cyrilzakka/clinical-trials huggingface dataset:
Cervical Epidural Pressure Measurement

Cervical epidural steroid injections

* The hanging drop (HD) technique is commonly used for identifying the cervical epidural space.
* The hanging drop (HD) technique is using the negative pressure in the epidural space.
* The subject of debate whether the epidural space exhibits negative pressure.
* In a previous study, EP might be influenced by body position
* No report or peer-reviewed literature to demonstrate the cervical epidural pressure (CEP) now.

The hypothesis of this study

* There is a difference in the cervical epidural pressure between in the prone and sitting positions
* To evaluate this hypothesis, CEPs in the prone and sitting groups were measured and compared in the two groups.
* Using a closed pressure measurement system
* Under fluoroscopic guidance.

Cervical epidural steroid injections (CESIs)

* For the conservative management of head, neck, and upper extremity pain
* Important to identify the epidural space for minimizing the chance of a dural puncture injection
* Dural puncture injection makes CESIs prone to rare but catastrophic complication like permanent spinal cord injury

The hanging drop (HD) technique

* Commonly used for identifying the cervical epidural space
* Using the negative pressure in the epidural space
* The subject of debate whether the epidural space exhibits negative pressure

In previous studies using a closed pressure measurement systems

* The epidural pressure (EP) was commonly positive at the thoracic level in the lateral decubitus position.
* EP was consistently negative only in the sitting position.
* EP might be influenced by body position.
* The patient should be sitting for using the HD technique.

No report or peer-reviewed literature to demonstrate the cervical epidural pressure (CEP) now.

The hypothesis of this study

* There is a difference in the cervical epidural pressure between in the prone and sitting positions
* To evaluate this hypothesis, CEPs in the prone and sitting groups were measured and compared in the two groups.
* Using a closed pressure measurement system
* Under fluoroscopic guidance.

Eligibility Criteria:
Inclusion Criteria:

* cervical radicular pain caused by herniated nucleus pulpous and spinal stenosis
* other conditions including herpes zoster-associated pain and sprain.

Exclusion Criteria:

* contraindications for CESIs, such as coagulopathy, patient refusal or infection at the proposed insertion site
* previous cervical spinal surgery
* pregnancy.
How Often Are Pharmacist Recommendations Followed by Emergency Physicians in Emergency Departments?

Clinical pharmacy has played a role in Emergency Departments (ED). The presence of pharmacists have been shown to reduce medication errors and improve the medication history taken at admission. In Denmark a recent study revealed that clinical pharmacists identified medication problems in 25% of all admission to the ED, of which 47 % were considered to be serious.

However, the pharmacist recommendations are of little value if they are not acknowledged or followed by the physicians.

The aim of the present study was to analyze how often and under which circumstances the physicians made use of pharmaceutical recommendations in an ED with a mixed patient population with special attention to those recommendations, which were of significant or disastrous importance.


Eligibility Criteria:
Inclusion Criteria:

- all acute admissions to emergency department who were treated with one or more drugs

Exclusion Criteria:

- children less than 15 years.
A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts

The FLOWGRAFT post-market clinical follow-up study is undertaken to show the safety and performance of FlowWeave Bioseal, FlowNit Bioseal, FlowLine Bipore and FlowLine Bipore Heparin (combined named as Vascular Grafts) in the treatment of arterial diseases, such as dissection, aneurysm, intramural hematoma (IMH), penetrating aortic ulcer (PAU), contained rupture, stenosis in the aorta or peripheral arteries (lower limbs). This includes the use of FlowWeave Bioseal or FlowNit Bioseal for debranching of the head vessels in an alone standing procedure. Furthermore, it includes the use of the FlowLine Bipore and FlowLine Bipore Heparin Grafts as arterious-venous (AV) shunt.

In this study, patients who receive a Vascular Graft for the treatment of arterial diseases (aneurysm, PAU, IMH, dissection, stenosis) of the aorta or peripheral arteries (lower limbs) or as an AV shunt will be observed. This includes patients in whom the Vascular Grafts are used for debranching or reconstruction of the head vessels. Participating physicians will be asked to provide the observations, that were collected during routine care. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection.

The period of data collection will be approximately 60 + 6 months (depending on the date of the last follow-up visit) from the date of intervention for each patient.

Eligibility Criteria:
Inclusion Criteria:

* Patient ≥ 18 years at time of written informed consent
* Patient was selected for treatment with a commercially available Vascular Graft of JOTEC
* Patient satisfies at least one of the following categories:

  * Acute (14 days) / subacute (15 - 90 days) dissection with double lumina in the aorta or peripheral artery / arteries (lower limb)
  * Chronic (\>90 days) dissection with double lumina in the aorta or peripheral artery / arteries (lower limb)
  * Aneurysm in the aorta or peripheral artery / arteries (lower limb)
  * IMH in the aorta or peripheral artery / arteries (lower limb)
  * PAU in the aorta or peripheral artery / arteries (lower limb)
  * Contained rupture in the aorta or peripheral artery / arteries (lower limb)
  * Stenosis in the aorta or peripheral artery / arteries (lower limb)
  * Debranching of head vessels
  * AV shunt
* Patient is willing and able to comply with all clinical study procedures and study visits.
* Patient has given written informed consent to participate in the study.

Exclusion Criteria:

* Patient has any other medical, social, or psychological problem that in the opinion of the investigator preclude them from receiving this treatment, procedures, and evaluations pre- and post-procedure.
* Patient is scheduled for reconstruction of the tibial artery
Study of Medical Ultrasound for Rhizarthrosis

It was never investigated which preservative non-invasive treatments are superior to treat rhizarthrosis. This randomized study compares the effect of 1. hand therapy vs. 2. therapeutic ultrasound vs. 3. hand therapy plus therapeutic ultrasound in the treatment of rhizarthrosis.


Eligibility Criteria:
Inclusion Criteria:

* Male and female patients aged 40 to 90 years
* Pain intensity in the region of the thumb base in pain phases ≥ 40 mm on the VAS of 0 to 100 mm (relative to the last 24 hours)
* Complaints for at least 3 months
* X-ray Stadium Eaton I-IV at least once secured

Exclusion Criteria:

* History of surgery on the affected hand, wrist or forearm
* Planned surgery in the next 8 months
* Anticoagulation (Marcumar, Heparin)
* Haemophilia, V. Willebrandt Jürgens syndrome, thrombocytopathy and other blood anomalies
* acute pain medication (\<7 days)
* Systemic medication with corticoids or immunosuppressants
* Intraarterticular injections or RSO within the last 3 months
* Pregnancy, lactation
* Insulin-dependent type I diabetes mellitus
* Significant cognitive impairment
* clinically relevant or progressive disease (e.g., liver, kidney, cardiovascular system, respiratory tract, vascular system, brain, metabolism, thyroid) that could affect the course of the study
* Malignant disease
* Simultaneous participation in an interventional study or participation in an interventional study in the last two months before study inclusion
* Clinically relevant addiction or substance abuse disorder (defined as alcohol, drug and drug abuse)
* Insufficient mental possibility of cooperation
* Therapy with oral anticoagulants (e.g., Marcumar)
* Suspected lack of compliance
* Medical, psychiatric or other conditions that restrict the patient's following abilities: to interpret the study information, to give informed consent, to adhere to the rules of the protocol, or to complete the study
Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

This is an extension study of Protocol CA194002 to allow 2 specific participants with basal cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923 to continue receiving the study drug. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.

The purpose of this study is to evaluate the safety and tolerability of BMS-833923 administered on an extension protocol in subjects with basal cell nevus syndrome (BCNS). This is an extension study of Protocol CA194002 to allow 2 specific participants with BCNS in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923, to continue receiving the study drug. In this open-label extension protocol, no new subjects will be recruited. The two BCNS subjects from Protocol CA194002 (subjects CA194002-1-14 and CA194002-1-25) will continue to receive BMS-833923 at the dose and schedule administered on CA194002 until fulfilling protocol criteria for discontinuation. These patients are receiving different doses: one being 60mg once every 2 weeks, and the other is receiving 300mg once daily. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.

Eligibility Criteria:
Inclusion Criteria:

* Signed consent
* Two specific study participants enrolled on protocol CA194002 at Princess Margaret Cancer Centre and remain on BMS-833923 at the time of study entry
* Women, age 18 years and above
* Agree to use methods to prevent pregnancy, not pregnant or breastfeeding

Exclusion Criteria:

* Known symptomatic brain metastasis
* A serious uncontrolled medical disorder or active infection, which would impair the ability of the patient to receive protocol therapy
* Gastrointestinal disease or surgery that could impact the absorption of study drug
* Inability to swallow oral medication
* Inability to be venipunctured and/or tolerate venous access
* Uncontrolled or significant cardiovascular
* Any other medical, psychiatric and/or social reason
* Have HIV, HepB, or HepC
* Exposure to immunosuppressants and immunotherapy concurrently with study treatment and up to 3 months
* Acceptable physical and laboratory test findings
* History of allergy to compounds chemically-related
Study of MAP0010 in Asthmatic Children and Adolescents

The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.


Eligibility Criteria:
Inclusion Criteria:

* Male or female asthmatic children/adolescents
* 1 to 18 years of age
* FEV1 greater than or equal to 50% predicted normal (where obtainable)
* Stable but symptomatic
* Diagnosis of asthma (per NIH criteria) at least 3 months before screening OR documented exacerbation or worsening of asthma or symptoms suggestive of asthma including nocturnal asthma, within 6 months of screening OR documented SAB use more than or at least once for symptom relief during the 4 days of run in with a total symptom score greater than or equal to 1 OR greater than or equal to 1 night disturbed due to asthma symptoms in previous month.

Exclusion Criteria:

* Any other significant childhood illness.
* Participated in any investigational clinical trial within the 30 days prior to screening.
* Use of any corticosteroid within 2 weeks of screening.
* Use of oral corticosteroid within 30 days of screening or prolonged use of oral corticosteroids within 12 weeks of screening.
* Use of inhaled long acting bronchodilators.
* Presumptive or documented history of upper or lower respiratory infection within 2 weeks before screening.
* Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.
* History suggestive (or diagnosis) of other concomitant lung disease.
Multi-center Study on Comprehensive Diagnosis and Treatment of Lower Limb Bone Defect Based on Three-dimensional Printing Technology

The clinical diagnosis and treatment of lower limb bone defect is a difficult problem in orthopedics. The traditional treatment has the shortcomings of long treatment period, no weight bearing in the early stage of the limb, weak mechanical strength, many complications, and difficulty in repairing deformed and large segment bone defects around the joint. The Orthopedics Department of Peking University Third Hospital, the lead unit of this study, developed the TCBridge system based on three-dimensional (3D) printing technology in the early stage, which is the first approved 3D printing lower limb long bone defect repair system in China. The system can achieve personalized and accurate repair of lower limb bone defects, and ensure patients to carry out limb weight and functional exercise safely in the early stage after surgery. On this basis, this study will establish a multi-center clinical case cohort to achieve accurate comprehensive diagnosis and treatment of lower limb bone defects, benefiting patients and contributing to society.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with traumatic lower limb bone defect;
2. Infected lower limb bone defect patients;
3. Patients with neoplastic lower limb bone defect;
4. The above reasons caused bone defects of more than 5CM
5. at least 18 years of age;
6. Sign an informed agreement and join the study cohort voluntarily.

Exclusion Criteria:

1. Patients who do not agree to the use of 3D printed microporous titanium alloy prostheses;
2. Patients who cannot tolerate surgery;
3. the subjects cannot comply with the follow-up or affect the scientific and integrity of the study;
4. Other patients who were not suitable for inclusion as assessed by clinicians.
Response of Topical Capsaicin in Alopecia Areata

It has been postulated that Alopecia Areata (AA) is, at least in part, a neurologically mediated disease. Research supporting this theory includes the finding that nerves surrounding the hair follicles are collapsed. We want to take this research a step further and show that not only are these perifollicular nerves collapsed, but that their function is also impaired.

To assess the function of perifollicular scalp nerves in AA we will look at the response of these nerves to the topical medication capsaicin. Under normal circumstances topical capsaicin is known to target nerves in the peripheral nervous system causing short-term release of the neuropeptide Substance P (SP) as well as long-term transient depletion of SP. We expect the AA patients will respond abnormally to topical capsaicin treatment.

Eligibility Criteria:
Inclusion Criteria:

* Must have alopecia totalis or universalis.
* Be in good health.
* Not be taking any medications including topical medications
* Be 18 years or older.
* Be willing to apply study medication or vehicle as directed, comply with instructions and commit to follow-up visits.
* Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.

Exclusion Criteria:

* Absence of extensive alopecia areata.
* People not in good health.
* People taking medications.
* Allergies to capsaicin.
* Presence of irritated or visibly inflamed scalp.
* Having had hair chemically treated (including colored hair, permed hair, etc.) within the month prior to study.
Attentional Focus and Prefrontal Cortical Activation in Older Adults and Patients With Parkinson's Disease (PD)

Attention may influence the motor performance and frontal activity. This study will examine the effect of different attentional focus: internal, external and divided attention (dual task) on prefrontal cortical activation (fNIRS) and on gait performance. Thirty older adults and thirty PD will participate in this study.

The subjects will be guided to walk at a normal pace while maintaining the required attentional focus. Subjects will walk on 20 m four times in each of the four different focus conditions :

1. no instructions about the attentional focus
2. internal focus on their feet movements,
3. external focus on two lines drawn on the floor,
4. divided attention (walking while performing an arithmetic task).

A fNIRS system will be used for the prefrontal cortex activation evaluation and FeetMe soles for gait analyses.

Eligibility Criteria:
Inclusion Criteria:

* For 2 groups :

  * Man or woman 60-85 years old
  * Informed consent obtained
* Group Parkinson : clinical diagnosis of idiopathic Parkinson's Disease, according to the UK Brain Bank criteria.

Exclusion Criteria:

* For 2 groups :

  * Assisted walker
  * Neurological (other than those resulting from Parkinson's disease), cardiologic, rheumatologic disorders
  * Disorders affecting gait.
  * Montreal Cognitive Assessment (MOCA) \< 24.
  * Concomitant medication likely to interfere with the results.
* Group Parkinson:

  * freezing
  * Hoehn et Yahr \> III
A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease

People with Parkinson Disease (PWPD) have significant problems with velocity, safety and dual tasking during walking that may be secondary to poor automaticity. Sensory functions, especially visual dependence and proprioceptive integration are critical for efficient walking and are often impaired. This home program compares the use of multimodal sensory feedback during stepping and balance exercises in PWPD to a group without the sensory feedback performing the same basic exercises.

Parkinson disease impairs motor and sensory functions. Automaticity of gait is lost increasing the use of higher center control of walking, leading to cognitive fatigue, slower movement and motor errors. People with Parkinson disease (PWPD) improve motor performance when external sensory cues, which bypass the faulty basal ganglia, are used during interventions. Enhancing proprioceptive, visual and vestibular cues that are critical for walking has the potential to improve gait and decrease cognitive fatigue by restoring automaticity.

This is a single-blinded randomized controlled study with repeated measures to evaluate the effects of a home exercise program with or without the addition of multi-modal sensory feedback (MMSF) in real-time on automaticity of gait and balance. PWPDs are randomly assigned to one of 2 home exercise groups. There are two 6 week exercise sessions with a 6 week of no exercises inter-spaced between them. The exercises promote rapid and large movement in stepping activities, balance using self-perturbation through single, leg swings and standing on a compliant surface for sensory re-weighting. People in the experimental group perform the program with real-time with MMSF. Participants are to progress exercises in speed and distance as well as performing with eyes closed to improve proprioceptive processing and automaticity.

Eligibility Criteria:
Inclusion Criteria:

* Medical diagnosis of Parkinson Disease
* A score of 26 or higher on the Mini-Mental Status Exam
* Able to stand from sitting and take 5 steps without assistance
* People who have been on the same dosages of medication for PD for 3 weeks or longer

Exclusion Criteria:

* Participating in an exercise program for less than 3 months
* Plans to change a current exercise program during the study
* Changes in medications that affect PD or its sequelea
Investigation of Changes in Lower Limb Muscles After Cerebrovascular Accident

The aim of this study is to investigate lower limb muscles after cerebrovascular accident

The aim of this study is to define and differentiate the changes in MMT properties related to the alterations in muscle tone of the lower limb in first-ever chronic stroke patients by using a 3D free-hand Ultrasonography (3DfUS) technique in combination with an instrumented spasticity assessment (IPSA). In these chronic stroke patients, the spontaneous neurological recovery is stabilized

Eligibility Criteria:
Inclusion Criteria:

* Definition of case population :

  o first ever stroke with spasticity of the lower limb.
* Definition of control :

  * first ever stroke without spasticity of the lower limb
  * healthy aged-matched subjects

Exclusion Criteria:

* Musculoskeletal or neurological problems affecting the lower limb
* Presence of other neurological pathology that could lead to spasticity, ataxia, dystonia
* Cognitive problems that impede measurements
* Severe co-morbidities
* Peripheral spastic medication
Postpartum ASA and NT-proBNP

This study is a double-blinded randomized-controlled trial in which patients will be randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum. The purpose of this study is to compare NT-proBNP levels at the 4-6 week postpartum visit between groups. There is currently no data on the maternal health effects associated with continuation of low-dose aspirin in the postpartum period. This study aims to fill a gap in the knowledge regarding the utility of low-dose aspirin following delivery.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age and older
* English-speaking
* postpartum
* have met USPSTF recommendations for low-dose aspirin use during pregnancy: \>1 high risk factor (history of preeclampsia in prior pregnancy, multifetal gestational, chronic hypertension, preexisting diabetes, renal disease, autoimmune disease) or \>2 moderate risk factors (nulliparity, obesity, family history of preeclampsia, sociodemographic characteristics, age 35 years or older, or personal history factors) and reported at least 50% compliance with aspirin during pregnancy.

Exclusion Criteria:

* hypersensitivity reaction to aspirin or other salicylates,
* history of gastrointestinal bleeding
* history of gastric or duodenal ulcers
* severe hepatic dysfunction
* bleeding disorders and diathesis
* known cardiac dysfunction with reduced ejection fraction, or are taking or prescribed ACE inhibitors.
* Patients who required ICU level care during their pregnancy will be excluded.